These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31918780)

  • 41. Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE).
    Duvignaud A; Jaspard M; Etafo IC; Serra B; Abejegah C; Gabillard D; Doutchi M; Alabi JF; Adedokun MA; Akinpelu AO; Oyegunle OO; Etafo J; Dede AO; Onyechi MN; Ireneh MU; Gbenga-Ayeni O; Fadiminiyi KG; Ehigbor PI; Ouattara E; Levy-Marchal C; Karcher S; N'guessan-Koffi L; Ahyi I; Amani E; Diabaté M; Siloué B; Schaeffer J; Augier A; Ogbaini-Emovon E; Salam AP; Horby P; Ahmed LA; Günther S; Adedosu AN; Anglaret X; Ayodeji OO; Malvy D
    Travel Med Infect Dis; 2020; 36():101557. PubMed ID: 31978611
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Progress and challenges of Lassa fever control in Nigeria.
    Adepoju P
    Lancet Infect Dis; 2019 Apr; 19(4):364. PubMed ID: 31002078
    [No Abstract]   [Full Text] [Related]  

  • 43. Delayed-onset paraparesis in Lassa fever: A case report.
    Duvignaud A; Doutchi M; Abejegah C; Etafo I; Jaspard M; Serra B; Tricaud E; Levy-Marchal C; Anglaret X; Ahmed LA; Adedosu AN; Malvy D; Ayodeji OO
    Int J Infect Dis; 2020 Mar; 92():49-52. PubMed ID: 31866549
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metagenomic surveillance uncovers diverse and novel viral taxa in febrile patients from Nigeria.
    Oguzie JU; Petros BA; Oluniyi PE; Mehta SB; Eromon PE; Nair P; Adewale-Fasoro O; Ifoga PD; Odia I; Pastusiak A; Gbemisola OS; Aiyepada JO; Uyigue EA; Edamhande AP; Blessing O; Airende M; Tomkins-Tinch C; Qu J; Stenson L; Schaffner SF; Oyejide N; Ajayi NA; Ojide K; Ogah O; Abejegah C; Adedosu N; Ayodeji O; Liasu AA; Okogbenin S; Okokhere PO; Park DJ; Folarin OA; Komolafe I; Ihekweazu C; Frost SDW; Jackson EK; Siddle KJ; Sabeti PC; Happi CT
    Nat Commun; 2023 Aug; 14(1):4693. PubMed ID: 37542071
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Retrospective Cohort Study of Lassa Fever in Pregnancy, Southern Nigeria.
    Okogbenin S; Okoeguale J; Akpede G; Colubri A; Barnes KG; Mehta S; Eifediyi R; Okogbo F; Eigbefoh J; Momoh M; Rafiu M; Adomeh D; Odia I; Aire C; Atafo R; Okonofua M; Pahlman M; Becker-Ziaja B; Asogun D; Okokhere P; Happi C; Günther S; Sabeti PC; Ogbaini-Emovon E
    Emerg Infect Dis; 2019 Aug; 25(8):1494-500. PubMed ID: 31310586
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mapping the zoonotic niche of Lassa fever in Africa.
    Mylne AQ; Pigott DM; Longbottom J; Shearer F; Duda KA; Messina JP; Weiss DJ; Moyes CL; Golding N; Hay SI
    Trans R Soc Trop Med Hyg; 2015 Aug; 109(8):483-92. PubMed ID: 26085474
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lassa fever outbreak continues across Nigeria.
    Bagcchi S
    Lancet Infect Dis; 2020 May; 20(5):543. PubMed ID: 32359466
    [No Abstract]   [Full Text] [Related]  

  • 48. Using modelling to disentangle the relative contributions of zoonotic and anthroponotic transmission: the case of lassa fever.
    Lo Iacono G; Cunningham AA; Fichet-Calvet E; Garry RF; Grant DS; Khan SH; Leach M; Moses LM; Schieffelin JS; Shaffer JG; Webb CT; Wood JL
    PLoS Negl Trop Dis; 2015 Jan; 9(1):e3398. PubMed ID: 25569707
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New methodologies for the estimation of population vulnerability to diseases: a case study of Lassa fever and Ebola in Nigeria and Sierra Leone.
    Kajero O; Del Rio Vilas V; Wood JLN; Lo Iacono G
    Philos Trans R Soc Lond B Biol Sci; 2019 Jul; 374(1776):20180265. PubMed ID: 31104602
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute Abdomen in Pediatric Patients With Lassa Fever: Prevalence and Response to Nonoperative Management.
    Akpede GO; Adetunji AE; Udefiagbon EO; Eluehike SO; Odike AI; Ewah-Odiase RO; Omosofe FO; Akerele JM; Atafo RO; Okonofua MO; Onyeke I; Oyedeji OA; Mbanefo K; Ogbaini-Emovon E; Okokhere PO; Günther S; Dongo AE
    J Pediatric Infect Dis Soc; 2019 Dec; 8(6):519-524. PubMed ID: 30272215
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genetic characterization of Lassa virus strains isolated from 2012 to 2016 in southeastern Nigeria.
    Oloniniyi OK; Unigwe US; Okada S; Kimura M; Koyano S; Miyazaki Y; Iroezindu MO; Ajayi NA; Chukwubike CM; Chika-Igwenyi NM; Ndu AC; Nwidi DU; Abe H; Urata S; Kurosaki Y; Yasuda J
    PLoS Negl Trop Dis; 2018 Nov; 12(11):e0006971. PubMed ID: 30500827
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lassa fever: Time to eradicate the deadly disease in Nigeria.
    Ohanu ME; Nwafia IN
    Niger J Clin Pract; 2019 Jan; 22(1):144-145. PubMed ID: 30666035
    [No Abstract]   [Full Text] [Related]  

  • 53. Simple framework for real-time forecast in a data-limited situation: the Zika virus (ZIKV) outbreaks in Brazil from 2015 to 2016 as an example.
    Zhao S; Musa SS; Fu H; He D; Qin J
    Parasit Vectors; 2019 Jul; 12(1):344. PubMed ID: 31300061
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice.
    Fisher-Hoch SP; Tomori O; Nasidi A; Perez-Oronoz GI; Fakile Y; Hutwagner L; McCormick JB
    BMJ; 1995 Sep; 311(7009):857-9. PubMed ID: 7580496
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Knowledge, Misperceptions, Preparedness, and Barriers towards Lassa Fever Control among Health Care Workers in a Tertiary Institution in Enugu, Nigeria.
    Ndu AC; Kassy WC; Ochie CN; Arinze-Onyia SU; Okeke TA; Aguwa EN; Okwor TJ; Chinawa A
    J Health Care Poor Underserved; 2019; 30(3):1151-1164. PubMed ID: 31422994
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lassa Fever-associated Stigmatization among Staff and Students of the University of Benin, Nigeria.
    Usifoh SF; Odigie AE; Ighedosa SU; Uwagie-Ero EA; Aighewi IT
    J Epidemiol Glob Health; 2019 Jun; 9(2):107-115. PubMed ID: 31241868
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria.
    Erameh C; Edeawe O; Akhideno P; Eifediyi G; Omansen TF; Wagner C; Sarpong F; Koch T; Wicha S; Kurth F; Duraffour S; Oestereich L; Pahlmann M; Okogbenin S; Ogbaini-Emovon E; Günther S; Ramharter M; Groger M
    BMJ Open; 2020 Apr; 10(4):e036936. PubMed ID: 32303517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lassa fever: a new appraisal.
    Monath TP
    Niger Med J; 1973 Jul; 3(3):162-3. PubMed ID: 16366355
    [No Abstract]   [Full Text] [Related]  

  • 59. Development of an RT-LAMP assay for the detection of Lassa viruses in southeast and south-central Nigeria.
    Pemba CM; Kurosaki Y; Yoshikawa R; Oloniniyi OK; Urata S; Sueyoshi M; Zadeh VR; Nwafor I; Iroezindu MO; Ajayi NA; Chukwubike CM; Chika-Igwenyi NM; Ndu AC; Nwidi DU; Maehira Y; Unigwe US; Ojide CK; Onwe EO; Yasuda J
    J Virol Methods; 2019 Jul; 269():30-37. PubMed ID: 30974179
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of a time-trend model for analyzing and predicting case-pattern of Lassa fever epidemics in Liberia, 2013-2017.
    Olugasa BO; Odigie EA; Lawani M; Ojo JF
    Ann Afr Med; 2015; 14(2):89-96. PubMed ID: 25693816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.